The analysis involved CD34+/CD38− cells from 3 newly diagnosed CML patients after checking the percentages of cells in each CD34/CD38 subpopulation (purity) before and following treatment with BK124.1. This evidence concerns the gene CD38 and chronic myelogenous leukemia, BCR-ABL1 positive.